ENGLEWOOD, Colo., June 10, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it will participate in an analyst-led fireside chat on an RBC Capital Markets 2024 Medical Device Strategy & Innovation Call at 11:00 AM ET on Thursday, June 13, 2024.
Shagun Singh, Medical Supplies & Devices Analyst, RBC Capital Markets and Thomas Sandgaard, Chairman, President, & Chief Executive Officer, Zynex, will participate in the fireside chat.
RBCCM 2024 Medical Device Strategy & Innovation Call: Zynex
Date: Thursday, June 13, 2024
Time: 11:00 AM – 12:00 PM ET
Web Link: https://www.veracast.com/webcasts/rbc/meetings/z71eMX.cfm
Registration for the live event is required. A replay of the webcast will also be available for two weeks following the event.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594
Last Trade: | US$2.16 |
Daily Volume: | 341,666 |
Market Cap: | US$68.800M |
December 12, 2024 December 05, 2024 October 24, 2024 September 04, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load